GPC1 and pancreatic adenocarcinoma: An earlier attempt to replicate the GPC-1 results by Melo et al. using a more clinically viable detection method showed that when using ELISA to detect GPC-1-enriched EVs, there was no significant difference between patients with pancreatic adenocarcinoma (PDAC) and patients with benign pancreatic conditions.